Liquid biopsy in early stage lung cancer.

Lung cancer is the leading cause of cancer-associated deaths worldwide. Surgery is the standard treatment for early-stage non-small cell lung cancer (NSCLC). However, 30% to 80% of these patients will die within 5 yearS of diagnosis. Circulating cell-free DNA (cfDNA) harbors pathologic characteristics of the original tumor, such as gene mutations or epigenetic alterations. Analysis of cfDNA has revolutionized the clinical care of advanced lung cancer patients undergoing targeted therapies. However, the low concentration of cfDNA in the blood of early-stage NSCLC patients has hampered its use for management of early disease. Continuing development of more specific and sensitive techniques for detection and analysis of cfDNA will soon enable its leverage in early stage and, perhaps, even screening settings. Therefore, cfDNA analysis may become a tool used for routine NSCLC diagnosis and for monitoring tumor burden, as well as for identifying hidden residual disease. In this review, we will focus on the current evidence of cfDNA in patients with early-stage NSCLC, new and upcoming approaches to identify circulating-tumor biomarkers, their clinical applications and future directions.

[1]  P. V. Van Schil,et al.  Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients. , 2017, Lung cancer.

[2]  A. Robles,et al.  Methylation analyses in liquid biopsy. , 2016, Translational lung cancer research.

[3]  E. Vasile,et al.  EGFR and KRAS mutational analysis in a large series of Italian non-small cell lung cancer patients: 2,387 cases from a single center. , 2016, Oncology reports.

[4]  R. Rosell,et al.  BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors , 2015, Melanoma research.

[5]  R. Rosell,et al.  cfDNA analysis from blood in melanoma. , 2015, Annals of translational medicine.

[6]  M. Tiseo,et al.  Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer. , 2015, Translational lung cancer research.

[7]  S. Stein,et al.  Circulating Cell-Free Tumour DNA in the Management of Cancer , 2015, International journal of molecular sciences.

[8]  E. Felip,et al.  Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. , 2015, JAMA oncology.

[9]  Jun Yokota,et al.  The Expression of Four Genes as a Prognostic Classifier for Stage I Lung Adenocarcinoma in 12 Independent Cohorts , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[10]  Ed Yong,et al.  Cancer biomarkers: Written in blood , 2014, Nature.

[11]  L. Diaz,et al.  Liquid biopsies: genotyping circulating tumor DNA. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Ash A. Alizadeh,et al.  An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage , 2013, Nature Medicine.

[13]  R. McCormack,et al.  First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study , 2013, British Journal of Cancer.

[14]  P. Holdgaard,et al.  The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC , 2013, British Journal of Cancer.

[15]  Carlota Costa,et al.  KRAS mutations in lung cancer. , 2013, Clinical lung cancer.

[16]  A. Jakobsen,et al.  The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. , 2013, Lung cancer.

[17]  E. Scarpi,et al.  Multiple Marker Detection in Peripheral Blood for NSCLC Diagnosis , 2013, PloS one.

[18]  S. Weroha,et al.  Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). , 2012, Clinical lung cancer.

[19]  R. Catarino,et al.  Circulating DNA: Diagnostic Tool and Predictive Marker for Overall Survival of NSCLC Patients , 2012, PloS one.

[20]  N. Rosenfeld,et al.  Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA , 2012, Science Translational Medicine.

[21]  D. Keys,et al.  Abstract 2100: Cancer biomarker research using castPCR technology , 2012 .

[22]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[23]  Liang Cheng,et al.  Molecular pathology of lung cancer: key to personalized medicine , 2012, Modern Pathology.

[24]  Koichi Goto,et al.  Epidermal Growth Factor Receptor Mutation Status in Circulating Free DNA in Serum: From IPASS, a Phase III Study of Gefitinib or Carboplatin/Paclitaxel in Non-small Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  G. Hampton,et al.  Evaluation of Circulating Tumor Cells and Circulating Tumor DNA in Non–Small Cell Lung Cancer: Association with Clinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib , 2011, Clinical Cancer Research.

[26]  Jeff Mellen,et al.  High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number , 2011, Analytical chemistry.

[27]  Kikuya Kato,et al.  Quantitative Detection of EGFR Mutations in Circulating Tumor DNA Derived from Lung Adenocarcinomas , 2011, Clinical Cancer Research.

[28]  Y. Yatabe,et al.  Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. , 2011, Lung cancer.

[29]  Klaus Pantel,et al.  Cell-free nucleic acids as biomarkers in cancer patients , 2011, Nature Reviews Cancer.

[30]  M. Ladanyi,et al.  Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  K. Kinzler,et al.  Detection and quantification of rare mutations with massively parallel sequencing , 2011, Proceedings of the National Academy of Sciences.

[32]  Yun Zheng,et al.  Methylation of multiple genes as a candidate biomarker in non-small cell lung cancer. , 2011, Cancer letters.

[33]  J. Shaw,et al.  Detection of HER2 amplification in circulating free DNA in patients with breast cancer , 2011, British Journal of Cancer.

[34]  V. Poletti,et al.  Increased Levels of Free Circulating Dna in Patients with Idiopathic Pulmonary Fibrosis , 2010, The International journal of biological markers.

[35]  John J. Crowley,et al.  国际肺癌研究会分期项目——采用外科治疗的非小细胞肺癌的预后因素和病理TNM分期 , 2010, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

[36]  M. Paci,et al.  Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer. , 2009, Lung cancer.

[37]  Issa J Dahabreh,et al.  Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database , 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[39]  K. Hemminki,et al.  Determination of allele frequency in pooled DNA: comparison of three PCR-based methods. , 2005, BioTechniques.

[40]  Frank Diehl,et al.  Detection and quantification of mutations in the plasma of patients with colorectal tumors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Greg L Perkins,et al.  Serum tumor markers. , 2003, American family physician.

[42]  U. Pastorino,et al.  Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[44]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[45]  L. Mariani,et al.  Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. , 2001, Cancer research.

[46]  Y. Lo,et al.  Plasma DNA as a prognostic marker in trauma patients. , 2000, Clinical chemistry.

[47]  T. Griffin,et al.  Single-nucleotide polymorphism analysis by MALDI-TOF mass spectrometry. , 2000, Trends in biotechnology.

[48]  J. Nikliński,et al.  Prognostic value of pretreatment CEA, SCC‐Ag and CA 19–9 levels in sera of patients with non‐small cell lung cancer , 1992, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[49]  C. Steinman.  Circulating DNA in systemic lupus erythematosus. Isolation and characterization. , 1984, The Journal of clinical investigation.

[50]  B. Shapiro,et al.  Determination of circulating DNA levels in patients with benign or malignant gastrointestinal disease , 1983, Cancer.

[51]  B. Shapiro,et al.  Free DNA in the serum of cancer patients and the effect of therapy. , 1977, Cancer research.

[52]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[53]  K. Nie,et al.  Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer , 2014, Tumor Biology.

[54]  S. Kobayashi,et al.  EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. , 2012, The Lancet. Oncology.

[55]  Lin Huan,et al.  Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer , 2010 .

[56]  S. Goodman,et al.  Circulating mutant DNA to assess tumor dynamics , 2008, Nature Medicine.

[57]  M. Spreeuwenberg,et al.  The Origin of Circulating Free DNA , 2007 .

[58]  V A Memoli,et al.  Soluble normal and mutated DNA sequences from single-copy genes in human blood. , 1994, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[59]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.

[60]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.